Literature DB >> 17222682

Endothelium dependent relaxation in rabbit genital resistance arteries is predominantly mediated by endothelial-derived hyperpolarizing factor in females and nitric oxide in males.

J S Morton1, V M Jackson, C J Daly, J C McGrath.   

Abstract

PURPOSE: In nongenital arteries a sex difference has been postulated in the dominant endothelium-derived relaxant factor(s), eg nitric oxide, prostacyclin or endothelial-derived hyperpolarizing factor. Knowledge of endothelium-derived relaxant factor mechanisms in genital tissues could influence the development of novel treatments for sexual dysfunction. We compared nitric oxide and endothelial-derived hyperpolarizing factor contributions to acetylcholine induced relaxation in the genital arteries of the 2 sexes.
MATERIALS AND METHODS: Male dorsal and cavernous penile arteries, and female extravaginal and intravaginal arteries from New Zealand White rabbits were studied. Acetylcholine concentration-vasodilator response curves were constructed in the presence of the nitric oxide synthase inhibitor Nomega-nitro-L-arginine methyl ester, K(+) channel blockers (apamin and charybdotoxin) or a combination. Indomethacin was present throughout to exclude prostacyclins.
RESULTS: Extravaginal artery relaxation was predominantly endothelial-derived hyperpolarizing factor induced. Apamin plus charybdotoxin decreased maximal relaxations from a mean +/- SEM of 77% +/- 4% to 23% +/- 3% in 6 preparations (p <0.01). However, nitric oxide and endothelial-derived hyperpolarizing factor contributed to overall function. Dorsal artery relaxation was largely nitric oxide induced. Nomega-nitro-L-arginine methyl ester decreased maximal relaxations from 90% +/- 3% to 41% +/- 9% (p <0.001) with no endothelial-derived hyperpolarizing factor involvement (p >0.05). In cavernous and intravaginal arteries nitric oxide and endothelial-derived hyperpolarizing factor contributed to acetylcholine induced relaxation, while nitric oxide predominated. Blocking nitric oxide synthase or K(+) channels indicated that myogenic tone and constitutive activity of endothelium-derived relaxant factors were present. Vasodilator nerve mediated responses were influenced by each with the former more effective.
CONCLUSIONS: Vaginal inflow arteries showed a dominance of endothelial-derived hyperpolarizing factor, contrasting with nitric oxide in penile arteries. Penile arteries followed the trend that endothelial-derived hyperpolarizing factor involvement increased with decreasing vessel caliber, while the reverse was demonstrated in female arteries.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222682     DOI: 10.1016/j.juro.2006.09.072

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Alpha(1A)-adrenoceptors mediate contractions to phenylephrine in rabbit penile arteries.

Authors:  J S Morton; C J Daly; V M Jackson; J C McGrath
Journal:  Br J Pharmacol       Date:  2006-11-20       Impact factor: 8.739

2.  Distinct endothelial pathways underlie sexual dimorphism in vascular auto-regulation.

Authors:  Melissa V Chan; Kristen J Bubb; Alastair Noyce; Inmaculada C Villar; Johan Duchene; Adrian J Hobbs; Ramona S Scotland; Amrita Ahluwalia
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

3.  Functional and molecular characterization of endothelium-dependent and endothelium-independent relaxant pathways in uterine artery of non-pregnant buffaloes.

Authors:  Udayraj P Nakade; Abhishek Sharma; Priyambada Kumari; Shirish Bhatiya; Sooraj V Nair; K N Karikaran; Vipin Sharma; Soumen Choudhury; Satish Kumar Garg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-09-07       Impact factor: 3.000

4.  Estrogen replacement enhances EDHF-mediated vasodilation of mesenteric and uterine resistance arteries: role of endothelial cell Ca2+.

Authors:  Natalie Z Burger; Olga Y Kuzina; George Osol; Natalia I Gokina
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-01-06       Impact factor: 4.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.